Host genetics predict clinical deterioration in HCV-related cirrhosis

Lindsay Y. King, Kara B. Johnson, Hui Zheng, Lan Wei, Thomas Gudewicz, Yujin Hoshida, Kathleen E. Corey, Tokunbo Ajayi, Nneka Ufere, Thomas F. Baumert, Andrew T. Chan, Kenneth K. Tanabe, Bryan C. Fuchs, Raymond T. Chung

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Single nucleotide polymorphisms (SNPs) in the epidermal growth factor ( EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown. We genotyped SNPs in EGF, PNPLA3, and IL28B from liver tissue from 169 patients with biopsy-proven HCV cirrhosis. We estimated risk of clinical deterioration, defined as development of ascites, encephalopathy, variceal hemorrhage, HCC, or liver-related death using Cox proportional hazards modeling. During a median follow-up of 6.6 years, 66 of 169 patients experienced clinical deterioration. EGF non-AA, PNPLA3 non-CC, and IL28B non-CC genotypes were each associated with increased risk of clinical deterioration in age, sex, and race-adjusted analysis. Only EGF non-AA genotype was independently associated with increased risk of clinical deterioration (hazard ratio [HR] 2.87; 95% confidence interval [CI] 1.31-6.25) after additionally adjusting for bilirubin, albumin, and platelets. Compared to subjects who had 0-1 unfavorable genotypes, the HR for clinical deterioration was 1.79 (95%CI 0.96-3.35) for 2 unfavorable genotypes and 4.03 (95%CI 2.13-7.62) for unfavorable genotypes for all three loci (Ptrend,0.0001). In conclusion, among HCV cirrhotics, EGF non-AA genotype is independently associated with increased risk for clinical deterioration. Specific PNPLA3 and IL28B genotypes also appear to be associated with clinical deterioration. These SNPs have potential to identify patients with HCV-related cirrhosis who require more intensive monitoring for decompensation or future therapies preventing disease progression.

Original languageEnglish (US)
Article numbere114747
JournalPloS one
Volume9
Issue number12
DOIs
StatePublished - Dec 12 2014
Externally publishedYes

Fingerprint

Viruses
Deterioration
Epidermal Growth Factor
Polymorphism
Nucleotides
Hazards
Liver
Genes
Genetics
Phospholipases
Biopsy
Interleukins
Platelets
Bilirubin
Albumins
Tissue
Monitoring
Proteins

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

King, L. Y., Johnson, K. B., Zheng, H., Wei, L., Gudewicz, T., Hoshida, Y., ... Chung, R. T. (2014). Host genetics predict clinical deterioration in HCV-related cirrhosis. PloS one, 9(12), [e114747]. https://doi.org/10.1371/journal.pone.0114747

Host genetics predict clinical deterioration in HCV-related cirrhosis. / King, Lindsay Y.; Johnson, Kara B.; Zheng, Hui; Wei, Lan; Gudewicz, Thomas; Hoshida, Yujin; Corey, Kathleen E.; Ajayi, Tokunbo; Ufere, Nneka; Baumert, Thomas F.; Chan, Andrew T.; Tanabe, Kenneth K.; Fuchs, Bryan C.; Chung, Raymond T.

In: PloS one, Vol. 9, No. 12, e114747, 12.12.2014.

Research output: Contribution to journalArticle

King, LY, Johnson, KB, Zheng, H, Wei, L, Gudewicz, T, Hoshida, Y, Corey, KE, Ajayi, T, Ufere, N, Baumert, TF, Chan, AT, Tanabe, KK, Fuchs, BC & Chung, RT 2014, 'Host genetics predict clinical deterioration in HCV-related cirrhosis', PloS one, vol. 9, no. 12, e114747. https://doi.org/10.1371/journal.pone.0114747
King, Lindsay Y. ; Johnson, Kara B. ; Zheng, Hui ; Wei, Lan ; Gudewicz, Thomas ; Hoshida, Yujin ; Corey, Kathleen E. ; Ajayi, Tokunbo ; Ufere, Nneka ; Baumert, Thomas F. ; Chan, Andrew T. ; Tanabe, Kenneth K. ; Fuchs, Bryan C. ; Chung, Raymond T. / Host genetics predict clinical deterioration in HCV-related cirrhosis. In: PloS one. 2014 ; Vol. 9, No. 12.
@article{4ad678f2c8f44fb3b515561d99950326,
title = "Host genetics predict clinical deterioration in HCV-related cirrhosis",
abstract = "Single nucleotide polymorphisms (SNPs) in the epidermal growth factor ( EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown. We genotyped SNPs in EGF, PNPLA3, and IL28B from liver tissue from 169 patients with biopsy-proven HCV cirrhosis. We estimated risk of clinical deterioration, defined as development of ascites, encephalopathy, variceal hemorrhage, HCC, or liver-related death using Cox proportional hazards modeling. During a median follow-up of 6.6 years, 66 of 169 patients experienced clinical deterioration. EGF non-AA, PNPLA3 non-CC, and IL28B non-CC genotypes were each associated with increased risk of clinical deterioration in age, sex, and race-adjusted analysis. Only EGF non-AA genotype was independently associated with increased risk of clinical deterioration (hazard ratio [HR] 2.87; 95{\%} confidence interval [CI] 1.31-6.25) after additionally adjusting for bilirubin, albumin, and platelets. Compared to subjects who had 0-1 unfavorable genotypes, the HR for clinical deterioration was 1.79 (95{\%}CI 0.96-3.35) for 2 unfavorable genotypes and 4.03 (95{\%}CI 2.13-7.62) for unfavorable genotypes for all three loci (Ptrend,0.0001). In conclusion, among HCV cirrhotics, EGF non-AA genotype is independently associated with increased risk for clinical deterioration. Specific PNPLA3 and IL28B genotypes also appear to be associated with clinical deterioration. These SNPs have potential to identify patients with HCV-related cirrhosis who require more intensive monitoring for decompensation or future therapies preventing disease progression.",
author = "King, {Lindsay Y.} and Johnson, {Kara B.} and Hui Zheng and Lan Wei and Thomas Gudewicz and Yujin Hoshida and Corey, {Kathleen E.} and Tokunbo Ajayi and Nneka Ufere and Baumert, {Thomas F.} and Chan, {Andrew T.} and Tanabe, {Kenneth K.} and Fuchs, {Bryan C.} and Chung, {Raymond T.}",
year = "2014",
month = "12",
day = "12",
doi = "10.1371/journal.pone.0114747",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Host genetics predict clinical deterioration in HCV-related cirrhosis

AU - King, Lindsay Y.

AU - Johnson, Kara B.

AU - Zheng, Hui

AU - Wei, Lan

AU - Gudewicz, Thomas

AU - Hoshida, Yujin

AU - Corey, Kathleen E.

AU - Ajayi, Tokunbo

AU - Ufere, Nneka

AU - Baumert, Thomas F.

AU - Chan, Andrew T.

AU - Tanabe, Kenneth K.

AU - Fuchs, Bryan C.

AU - Chung, Raymond T.

PY - 2014/12/12

Y1 - 2014/12/12

N2 - Single nucleotide polymorphisms (SNPs) in the epidermal growth factor ( EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown. We genotyped SNPs in EGF, PNPLA3, and IL28B from liver tissue from 169 patients with biopsy-proven HCV cirrhosis. We estimated risk of clinical deterioration, defined as development of ascites, encephalopathy, variceal hemorrhage, HCC, or liver-related death using Cox proportional hazards modeling. During a median follow-up of 6.6 years, 66 of 169 patients experienced clinical deterioration. EGF non-AA, PNPLA3 non-CC, and IL28B non-CC genotypes were each associated with increased risk of clinical deterioration in age, sex, and race-adjusted analysis. Only EGF non-AA genotype was independently associated with increased risk of clinical deterioration (hazard ratio [HR] 2.87; 95% confidence interval [CI] 1.31-6.25) after additionally adjusting for bilirubin, albumin, and platelets. Compared to subjects who had 0-1 unfavorable genotypes, the HR for clinical deterioration was 1.79 (95%CI 0.96-3.35) for 2 unfavorable genotypes and 4.03 (95%CI 2.13-7.62) for unfavorable genotypes for all three loci (Ptrend,0.0001). In conclusion, among HCV cirrhotics, EGF non-AA genotype is independently associated with increased risk for clinical deterioration. Specific PNPLA3 and IL28B genotypes also appear to be associated with clinical deterioration. These SNPs have potential to identify patients with HCV-related cirrhosis who require more intensive monitoring for decompensation or future therapies preventing disease progression.

AB - Single nucleotide polymorphisms (SNPs) in the epidermal growth factor ( EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown. We genotyped SNPs in EGF, PNPLA3, and IL28B from liver tissue from 169 patients with biopsy-proven HCV cirrhosis. We estimated risk of clinical deterioration, defined as development of ascites, encephalopathy, variceal hemorrhage, HCC, or liver-related death using Cox proportional hazards modeling. During a median follow-up of 6.6 years, 66 of 169 patients experienced clinical deterioration. EGF non-AA, PNPLA3 non-CC, and IL28B non-CC genotypes were each associated with increased risk of clinical deterioration in age, sex, and race-adjusted analysis. Only EGF non-AA genotype was independently associated with increased risk of clinical deterioration (hazard ratio [HR] 2.87; 95% confidence interval [CI] 1.31-6.25) after additionally adjusting for bilirubin, albumin, and platelets. Compared to subjects who had 0-1 unfavorable genotypes, the HR for clinical deterioration was 1.79 (95%CI 0.96-3.35) for 2 unfavorable genotypes and 4.03 (95%CI 2.13-7.62) for unfavorable genotypes for all three loci (Ptrend,0.0001). In conclusion, among HCV cirrhotics, EGF non-AA genotype is independently associated with increased risk for clinical deterioration. Specific PNPLA3 and IL28B genotypes also appear to be associated with clinical deterioration. These SNPs have potential to identify patients with HCV-related cirrhosis who require more intensive monitoring for decompensation or future therapies preventing disease progression.

UR - http://www.scopus.com/inward/record.url?scp=84917737176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84917737176&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0114747

DO - 10.1371/journal.pone.0114747

M3 - Article

C2 - 25504078

AN - SCOPUS:84917737176

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e114747

ER -